Intravascular ULTrasound Guided Versus Conventional Angiography Guided Strategy to Deploy Zotarolimus and Everolimus Eluting Third Generation Stents in the Long Coronary Artery Lesions: ULTRA-ZET Trial
NCT01979744 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 568
Last updated 2019-03-28
Summary
Although first generation DES reduced instent restenosis, still remained the unsolved problems such as stent thrombosis and restenosis in the era of DES. Second generation DES had been developed to improve the biocompatibility of stent coating focused on polymer compared to first generation DES, so that second generation stents showed better outcomes compared with first generation DES. On the other hands, in third generation DES, further refinement of DES involved more flexible stent platform. Promus ElementTM (Everolimus eluting stent, Boston Scientific, Nastick, MA) and Resolute Integrity® (Zotarolimus eluting stent, Medtronic Vascular, Santa Rosa, CA) are the third generation drug eluting stents which are designed to increase flexibility. In previous randomized controlled studies, both of these stents have shown at least non-inferior angiographic and clinical outcomes compared to second generation DES. However, there is lack of data about comparison of angiographic and clinical outcomes between Promus ElementTM and Resolute Integrity®.
IVUS is one of the widely used intracoronary imaging devices to provide more reproducible and accurate information about coronary anatomy than angiography in current practice.8 Optimal stent expansion assessed by intravascular ultrasound (IVUS) has been reported as an important factor to prevent stent thrombosis or restenosis.9 Accordingly, there have been many studies to evaluate the procedural or clinical benefit of IVUS guided angioplasty. However, The clinical benefit of IVUS-guided angioplasty with stent implantation is still in a controversy. In the previous studies, IVUS-guided stent implantation showed positive or negative beneficial effect on clinical outcomes according to their study subjects. However, the stents used in the previous studies are less useful in current practice of cardiology and there is lack of data of 3rd generation DES, which have different stent profiles and outcomes with their predecessors.
Thus we would perform a prospective randomized study in order to compare the efficacy of IVUS-guided angioplasty with conventional angioplasty-guided procedure in the long coronary lesion. Our main hypothesis is IVUS-guided 3rd generation DES implantation in the long coronary lesions would have better clinical outcomes compared with conventional angiography-guided strategy. We also intend to assess the clinical outcomes after Promus ElementTM and Resolute Integrity® implantation.
Conditions
Interventions
- PROCEDURE
-
IVUS guided percutaneous coronary angioplasty with Resolute integrity stent insertion
Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
- DEVICE
-
Angiography guided percutaneous coronary angioplasty with Resolute integrity stent insertion
Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
- DEVICE
-
Angiography guided percutaneous coronary angioplasty with Promus element stent implantation
Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
- PROCEDURE
-
Angiography guided percutaneous coronary angioplasty with Promus element stent implantation
Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
Sponsors & Collaborators
-
Yonsei University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 19 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-10-31
- Primary Completion
- 2017-10-31
- Completion
- 2017-10-31
Countries
- South Korea
Study Locations
More Related Trials
-
Quantitative Coronary Angiography Versus Intravascular Ultrasound GUIDancE for Drug-Eluting Stent Implantation
NCT02978456 ·Status: COMPLETED ·Phase: NA
-
Ultrathin DES in Complex PCI Scenarios: the ULTRA a Multicenter Study
NCT05205148 ·Status: UNKNOWN
-
BES, EES, and ZES-R in Real World Practice
NCT01397175 ·Status: TERMINATED ·Phase: NA
-
Registry to Evaluate the Efficacy of Zotarolimus-Eluting Stent
NCT00960908 ·Status: UNKNOWN
-
LONG-DES VI (Drug Eluting Stent for Long Lesions in Coronary Artery)
NCT01489761 ·Status: TERMINATED ·Phase: PHASE4
-
Comparison of Neointimal Coverage Between Zotarolimus Eluting Stent and Everolimus Eluting Stent
NCT00894062 ·Status: COMPLETED ·Phase: PHASE4
-
Neointimal Coverage After Implantation of Biolimus Eluting Stent With Biodegradable Polymer: Optical Coherence Tomographic Assessment According to the Treatment of Dyslipidemia and Hypertension and the Types of Implanted Drug-eluting Stents
NCT01502904 ·Status: COMPLETED ·Phase: PHASE4
-
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen
NCT01267734 ·Status: UNKNOWN ·Phase: PHASE4
-
Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-IV: (LONG-DES-IV)
NCT01186094 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Outcomes of EES Implantation for Unprotected Left Main Coronary Artery Stenosis (PRE-COMBAT 2)
NCT01348022 ·Status: COMPLETED
-
Comparison of Drug Eluting Balloon and Drug Eluting Stent
NCT01539603 ·Status: COMPLETED ·Phase: PHASE2
-
The Efficacy of Three Different Limus Agent-Eluting Stents to Prevent Restenosis
NCT00332397 ·Status: COMPLETED ·Phase: PHASE4
-
Focal In-stent Restenosis After Drug-Eluting Stent
NCT00485004 ·Status: COMPLETED ·Phase: PHASE4
-
An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System
NCT01638507 ·Status: COMPLETED ·Phase: NA
-
ComparisiOn of Neointimal coVerage betwEen ZES and EES Using OCT at 3 Months
NCT01091740 ·Status: COMPLETED ·Phase: PHASE4
-
IVUS Controlled Stenting
NCT02128412 ·Status: UNKNOWN ·Phase: NA
-
Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-VII: Sirolimus-eluting (Ultimaster) vs. Everolimus-Eluting Stents (Xience)
NCT03484234 ·Status: TERMINATED ·Phase: NA
-
Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice
NCT01186133 ·Status: RECRUITING
-
Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III (LONG-DES-III)
NCT01078038 ·Status: COMPLETED ·Phase: PHASE4
-
A Randomized Comparison of Clinical Outcomes Between Everolimus-eluting Bioresorbable Vascular Scaffold Versus Everolimus-eluting Metallic Stent in Long Coronary Lesions
NCT02796157 ·Status: UNKNOWN ·Phase: NA
-
Post-dilatation for Optimization of Drug-eluting Stents (DES) Deployment Assessed by Intravascular Ultrasound Multicenter Analysis
NCT01103765 ·Status: UNKNOWN ·Phase: PHASE4
-
Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents
NCT00638794 ·Status: COMPLETED
-
Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated with Percutaneous Coronary Intervention
NCT06692140 ·Status: RECRUITING ·Phase: NA
-
Late Stent Strut Apposition and Coverage After Drug-Eluting Stent Implantation by OCT in Patients With AMI
NCT02770651 ·Status: UNKNOWN
-
A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
NCT02579031 ·Status: COMPLETED ·Phase: NA